Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease

Circulation Research

Volumn 82, Issue 10, 1998, Pages 1023-1028

  Morishita, Ryuichi ^a   Higaki, Jitsuo ^a   Tomita, Naruya ^a   Ogihara, Toshio ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Cis element decoy; Gene regulation; Glomerulonephritis; Myocardial infarction; Restenosis

Indexed keywords

CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; OLIGODEOXYNUCLEOTIDE; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ARTERY INTIMA PROLIFERATION; CIS TRANS ISOMERISM; GENE EXPRESSION REGULATION; GENE THERAPY; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SHORT SURVEY; TECHNOLOGY; TRANSCRIPTION REGULATION;

EID: 0032103247     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.82.10.1023     Document Type: Short Survey

References (62)

1. Isner JM. Oligonucleotide therapeutics: novel cardiovascular targets. Nat Med. 1997;3:834-835.
2. Bielinska A, Shivdasani RA, Zhang L, Nabel GJ. Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science. 1990;250:997-1000.
3. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A novel molecular strategy using cis element "decoy" of E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci U S A. 1995;92:5855-5859.
4. Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T. In vivo transaction of cis element "decoy" against NFkB binding site prevented myocardial infarction as gene therapy. Nat Med. 1997;3:894-899.
5. Sawa Y, Morishita R, Suzuki K, Kagisaki K, Kaneda Y, Maeda K, Kadoba K, Matsuda H. A novel strategy for myocardial protection using in vivo transfection of cis element "decoy" against NFkB binding site: evidence for a role of NFkB in ischemic-reperfusion injury. Circulation, 1997;965(suppl II):II-280-II-285.
6. Tomita N, Kim J, Gibbons GH, Baran D, Ogborn M, Stahl RAK, Tomita S, Zhang L, Kaneda Y, Dzau VJ. In vivo gene therapy of anti-Thy 1 nephritis using E2F decoy oligonucleotides [abstract]. J Am Soc Nephrol. 1995;6:887.
7. Tomita N, Morishita R, Higaki J, Kaneda Y, Ogihara T. Potential gene therapy to glomerular disease: application of transcriptional factor decoy approach [abstract]. Nephrology. 1997;3:S33.
8. Morishita R, Higaki J, Tomita N, Aoki M, Moriguchi A, Tamura K, Murakami K, Kaneda Y, Ogihara T. Role of transcriptional cis-elements. angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation. Hypertension. 1996;27:502-507.
9. Sharma HW, Perez JR, Higgins-Sochaski K, Hsiao R, Narayanan R. Transcription factor decoy approach to decipher the role of NF-kappa B in oncogenesis. Anticancer Res. 1996;16:61-69.
10. Sharma HW, Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res. 1996;16:589-596.
11. Roshak AK, Jackson JR, McGough K, Chabot-Fletcher M, Mochan E, Marshall LA. Manipulation of distinct NFkappaB proteins alters interleukin-1beta-induced human rheumatoid synovial fibroblast prostaglandin E2 formation. J Biol Chem. 1996;271:31496-31501.
12. Clusel C, Meguenni S, Elias I, Vasseur M, Blumenfeld M. Inhibition of HSV-1 proliferation by decoy phosphodiester oligonucleotides containing ICP4 recognition sequences. Gene Expr. 1995;4:301-309.
13. Yamada T, Horiuchi M, Morishita R, Zhang L, Pratt RE, Dzau VJ. In vivo identification of a negative regulatory element in the mouse renin gene using direct gene transfer. J Clin Invest. 1995;96:1230-1237.
14. di-Fagagna FD, Marzio G, Gutierrez MI, Kang LY, Falaschi A, Giacca M. Molecular and functional interactions of transcription factor USF with the long terminal repeat of human immunodeficiency virus type 1. J Virol. 1995;69:2765-2775.
15. Tanaka H, Vickart P, Bertrand JR, Rayner B, Morvan F, Imbach JL, Paulin D, Malvy C. Sequence-specific interaction of alpha-beta-anomeric double-stranded DNA with the p50 subunit of NF kappa B: application to the decoy approach. Nucleic Acids Res. 1994;22:3069-3074.
16. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem. 1997;272:601-608.
17. Gambarotta G, Boccaccio C, Giordano S, Ando M, Stella MC, Comoglio PM. Ets up-regulates MET transcription. Oncogene. 1996;13:1911-1917.
18. Stein CA, Cohen JS. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 1988;48:2659-2668.
19. Dzau VJ, Horiuchi M. In vivo gene transfer and gene modulation in hypertension research. Hypertension. 1996;28:1132-1137.
20. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Single intraluminal delivery of antisense cdc 2 kinase and PCNA oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993;90:8474-8479.
21. Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, Fukamizu A, Murakami K, Kaneda Y, Ogihara T. Transient decrease in high blood pressure by in vivo transfer of antisense Oligodeoxynucleotides against rat angiotensinogen. Hypertension. 1995;26:131-136.
22. Latchhman DS. Transcription factor mutations and disease. N Engl J Med. 1996;334:28-33.
23. Sullenger BA, Gallardo HF, Lingers GE, Giboa E. Overexpression of TAR sequence renders cells resistant to human immunodeficiency virus replication. Cell. 1990;63:601-608.
24. Bahner I, Kearns K, Hao QL, Smogorzewska EM, Kohn DB. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J Virol. 1996;70:4352-4360.
25. Lee SW, Gallardo HF, Gaspar O, Smith C, Gilboa E. Inhibition of HIV-1 in CEM cells by a potent TAR decoy. Gene Ther. 1995;2:377-384.
26. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
27. Clowes AW, Clowes MM, Fingerle J, Reidy MA. Regulation of smooth muscle cell growth in injured artery. J Cardiovasc Pharmacol. 1989;14:S12-S15.
28. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
29. Weintraub SJ, Prater CA, Dean DC. Retinoblastoma protein switches the E2F site from positive to negative element. Nature. 1992;358:259-261.
30. Pagano M, Draetta G, Durr J. Association of cdk 2 kinase with the transcription factor E2F during S phase. Science. 1992;255:1144-1147.
31. Chow J, Hartley RB, Jagger C, Dilly SA. ICAM-1 expression in renal disease. J Clin Pathol. 1992;45:880-884.
32. Floege J, Eng E, Young BA, Johnson R. Factors involved in the regulation of mesangial cell proliferation in vitro and in vivo. Kidney Int. 1993;39:S47-S54.
33. Sterzel RB, Schulze-Lohoff E, Marx M. Cytokines and mesangial cells. Kidney Int. 1993;39:S26-S31.
34. Egido J, Gomez-Chiarri M, Ortiz A, Bustos C, Alonso J, Gomez-Guerrero C, Gomez-Garre D, Lopez-Armada MJ, Plaza J, Gonzalez E. Role of tumor necrosis factor-alpha in the pathogenesis of glomerular diseases. Kidney Int. 1993;39:S59-S64.
35. Herskowitz A, Choi S, Ansari AA, Wesselingh S. Cytokine mRNA expression in postischemic/reperfused myocardium. Am J Pathol. 1995;146:419-428.
36. Kukielka GL, Smith CW, LaRosa GJ, Manning AM, Mendoza LH, Daly TJ, Hughes BJ, Youker KA, Hawkins HK, Michael LH, Rot A, Entman ML. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo. J Clin Invest. 1995;95:89-103.
37. Kukielka GL, Entman ML. Adhesion molecule-dependent cardiovascular injury. In: Poste G, Metcalf B, eds. Cellular Adhesion: Molecular Definition to Therapeutic Potential. New York, NY: Plenum Publishing Corp; 1995;187-212.
38. Lenardo MJ, Baltimore D. NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell. 1989;58:227-229.
39. Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol. 1990;:10:2327-2334.
40. Satriano J, Schlondorff. Activation of attenuation of transcriptional factor NF-kB in mouse glomerular cells in response to tumor necrosis factor-α, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate. J Clin Invest. 1994;94:1629-1636.
41. Neish AS, Williams AJ, Palmer HJ, Whitley MZ, Collins T. Functional analysis of the human vascular cell adhesion molecule 1 promoter. J Exp Med. 1992;176:1583-1593.
42. Brennan DC, Jevnikar AM, Takei F, Reubin-Kelley VE. Mesangial cell accessory functions: mediation by intracellular adhesion molecule-1. Kidney Int. 1990;38:1039-1046.
43. Morishita R, Gibbons GH, Ellison KE, Nakajima M, Leyen HVL, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. Intimal hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J Clin Invest. 1994;93:1458-1464.
44. Morishita R, Gibbons GH, Kaneda Y, Ogihara T, Dzau VJ. Pharmacokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall: enhanced therapeutic utility for restenosis by HVJ-liposome method. Gene. 1994;149:13-19.
45. Chu BC, Orgel LE. The stability of different forms of double-stranded decoy DNA in serum and nuclear extracts. Nucleic Acids Res. 1992;20:5857-5858.
46. Sedor JR, Konieczkowski M, Huang S, Gronich JH, Nakazato Y, Gordon G, King CH. Cytokines, mesangial cell activation and glomerular injury. Kidney Int. 1993;39:S65-S70.
47. Navab M, Fogelman AM, Berliner JA, Territo MC, Demer LL, Frank JS, Watson AD, Edwards PA, Lusis AJ. Pathogenesis of atherosclerosis. Am J Cardiol. 1995;76:18C-23C.
48. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-1722.
49. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
50. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 1989;243:375-378.
51. Gibson I. Antisense approaches to the gene therapy of cancer-"Recnac." Cancer Metastasis Rev. 1996;15:287-299.
52. Khaled Z, Benimetskaya L, Zeltser R, Khan T, Sharma HW, Narayanan R, Stein CA. Multiple mechanisms may contribute to the cellular antiadhesive effects of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1996;24:737-775.
53. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB, Lott FD, Martin FH, Pierce GF, Simonet L, Farrell CL. The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A. 1995;92:4051-4055.
54. Srinivasan SK, Iversen P. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides. J Clin Lab Anal. 1995;9:129-137.
55. Henry SP, Bolte H, Auletta C, Kombrust DJ. Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology. 1997;120:145-155.
56. Cornish KG, Iversen P, Smith L, Arneson M, Bayever E. Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun. 1993;3:239.
57. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, Kornbrust DJ. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther. 1997;281:810-816.
58. Crooke ST. Progress in antisense therapeutics. Hematol Pathol. 1995;9:59-72.
59. Tomita N, Morishita R, Higaki J, Tomita S, Aoki M, Kaneda Y, Ogihara T. Role of angiotensinogen in blood pressure regulation in normotensive rats: application of a "loss of function" approach. J Hypertens. 1995;131:767-1774.
60. Fukamizu A, Takahashi S, Seo S, Tada M, Tanimoto K, Uehara S, Murakami K. Structure and expression of the human angiotensinogen gene: identification of a unique and highly active promoter. J Biol Chem. 1990;265:7576-7582.
61. Tamura K, Umehara S, Ishii M, Tanimoto K, Murakami K, Fukamizu A. Molecular mechanism of transcriptional activation of angiotensinogen gene by proximal promoter. J Clin Invest. 1994;93:1370-1379.
62. Mann MJ, Whittemore AD, Donaldson MC, Belkin MA, Orav EJ, Polak J, Dzau VJ. Preliminary clinical experience with genetic engineering of human vein grafts: evidence for target gene inhibition [abstract]. Circulation. 1997;96(suppl I):I-4.